18 and older, any sex, with Pleural Mesothelioma or Peritoneal Mesothelioma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Clinical Response Rate (PR+CR)Primary· 36 months
Clinical response is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is complete disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
Complete Response
Group
Value
95% CI
IMC-A12 Monotherapy in Patients
0
Partial Response
Group
Value
95% CI
IMC-A12 Monotherapy in Patients
0
Safety of IMC-A12 in Patients With MesotheliomaSecondary· Date treatment consent signed to date off study, approximately 36 months
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.
Group
Value
95% CI
IMC-A12 Monotherapy in Patients
20
Progression Free Survival (PFS)Secondary· To study completion, an average of 3 years
Progression Free Survival is defined as the time interval from the start of treatment to documented evidence of disease progression. Progressive disease is at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study longest diameter (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progression).
Group
Value
95% CI
IMC-A12 Monotherapy in Patients
1.8
1.4 – 5.5
Overall Survival (OS)Secondary· To study completion, an average of 3 years
Overall survival is the time interval from the start of treatment to the date of death.
Group
Value
95% CI
IMC-A12 Monotherapy in Patients
5.5
2.1 – 12.2
Adverse events — posted to ClinicalTrials.gov
Time frame: Date treatment consent signed to date off study, approximately 36 months..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
IMC-A12 Monotherapy in Patients
Serious: 19/20 (95%)
Deaths: 16/20
Serious adverse events (39 terms)
Reaction
System
IMC-A12 Monotherapy in Pat…
Death NOS
General disorders
—
Fatigue
General disorders
—
Neoplasms benign, mailgnant and unspecified (incl cysts and polyps)-Other, specify
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Background:
Background:
\- IMC-A12, a new cancer treatment that has not yet been approved by the U.S. Food and Drug Administration, is an antibody that is designed to block the effects of a protein called Type I Insulin-Like Growth Factor (IGF-1R). IMC-A12 blocks the receptors in cells that respond to IGF-1R, which are thought to play an important role in helping cancer cells to grow and divide. Researchers are interested in determining whether IMC-A12 is an effective treatment for individuals who have mesothelioma that has not responded to standard chemotherapy.
Objectives:
\- To evaluate the safety and effectiveness of IMC-A12 treatment in individuals with mesothelioma who have previously had chemotherapy.
Eligibility:
\- Individuals at least 18 years of age who have been diagnosed with mesothelioma that has not responded to chemotherapy.
Design:
* Eligible participants will be screened with a full physical examination and medical history, blood and urine samples, and imaging studies.
* Participants will receive IMC-A12 once every 3 weeks (21-day cycle), and will be evaluated before the start of each new cycle with blood tests and imaging studies if needed.
* Treatment cycles will continue for as long as needed, unless severe side effects develop or the disease progresses.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT01182883 — A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tum
· Phase 1
· withdrawn
Other recruiting trials for Pleural Mesothelioma
Currently open trials in the same condition.
NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
· Phase 1
· recruiting
NCT06790082 — The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
· Phase 2
· recruiting
NCT06362369 — A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
· Phase 1, PHASE2
· recruiting
NCT06410625 — Evaluation of Response by FLT PET in Mesothelioma
· NA
· recruiting
NCT05086692 — A Beta-only IL-2 ImmunoTherapY Study
· Phase 1, PHASE2
· recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem
· Phase 1, PHASE2
· recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem
· Phase 2, PHASE3
· not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa
· Phase 2
· recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After
· Phase 1
· not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 10 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01160458.